Gilead Sciences Inc. (NASDAQ:GILD) traded down 1.8% during trading on Monday . The stock traded as low as $77.63 and last traded at $78.33, with a volume of 10,657,487 shares traded. The stock had previously closed at $79.77.

Several equities research analysts have recently commented on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $116.00 target price (down from $120.00) on shares of Gilead Sciences in a research report on Wednesday, May 4th. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a report on Saturday, May 14th. Morgan Stanley restated a “hold” rating on shares of Gilead Sciences in a report on Sunday, May 29th. Jefferies Group restated a “hold” rating and set a $96.00 price target on shares of Gilead Sciences in a report on Sunday, June 12th. Finally, Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, August 21st. Ten analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $106.74.

The company has a 50 day moving average of $81.86 and a 200-day moving average of $87.05. The company has a market capitalization of $102.66 billion and a PE ratio of 6.828.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. During the same quarter in the previous year, the business earned $3.15 EPS. The company’s quarterly revenue was down 5.7% on a year-over-year basis. Equities analysts predict that Gilead Sciences Inc. will post $11.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Wednesday, September 14th.

In related news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction on Monday, June 6th. The shares were sold at an average price of $86.94, for a total value of $9,737,280.00. Following the sale, the chief executive officer now owns 1,170,963 shares in the company, valued at $101,803,523.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman John C. Martin sold 100,000 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the completion of the sale, the chairman now owns 4,119,727 shares in the company, valued at approximately $349,064,468.71. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have recently bought and sold shares of GILD. Mizuho Trust & Banking Co. Ltd. boosted its position in Gilead Sciences by 1.0% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,277,664 shares of the biopharmaceutical company’s stock worth $232,686,000 after buying an additional 23,105 shares during the period. TrimTabs Asset Management LLC boosted its position in Gilead Sciences by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 19,871 shares of the biopharmaceutical company’s stock worth $2,011,000 after buying an additional 369 shares during the period. Tredje AP fonden boosted its position in Gilead Sciences by 33.5% in the fourth quarter. Tredje AP fonden now owns 276,806 shares of the biopharmaceutical company’s stock worth $28,010,000 after buying an additional 69,393 shares during the period. Sawtooth Asset Management Inc. boosted its position in Gilead Sciences by 521.2% in the fourth quarter. Sawtooth Asset Management Inc. now owns 31,037 shares of the biopharmaceutical company’s stock worth $3,141,000 after buying an additional 26,041 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its position in Gilead Sciences by 3.0% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 722,425 shares of the biopharmaceutical company’s stock worth $73,102,000 after buying an additional 21,123 shares during the period.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.